U.S. Markets closed

Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?

Zacks Equity Research

Shares of ImmunoGen, Inc. IMGN have been massively up 192.7% this year so far, outperforming the industry’s registered 4.3% increase. Let’s analyze the factors that led to this rally.

ImmunoGen’s rapid pipeline progress along with positive readouts and strategic collaborations has pushed its share price up consistently.

ImmunoGen has made a significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine this year. The candidate is being evaluated in a phase III study (FORWARD I) on as a single-agent therapy for treating patients with platinum-resistant ovarian cancer.

The company has presently activated over 90 sites for enrolment under the trial, which it aims to complete by the middle of 2018. Also, the candidate is being evaluated in three phase I expansion cohorts on 113 ovarian cancer patients. In May, the company reported positive data from the study which demonstrated promising safety and efficacy profile of the candidate.

Meanwhile, combination regimens with mirvetuximab soravtansine in ovarian cancer are also being evaluated in phase Ib/II FORWARD II study. The FORWARD II trial consists of cohorts assessing mirvetuximab soravtansine in combination with Roche's RHHBY Avastin and Merck’s MRK Keytruda.

In May, ImmunoGen had reported initial data from this study, showing mirvetuximab soravtansine with potential to complement the currently available therapies for the indication. Approval for any of these combination regimes will significantly expand the eligible patient population for mirvetuximab soravtansine.

An approval of mirvetuximab soravtansine would be a huge boost to ImmunoGen, given its immense commercial potential in the target market. Ovarian cancer results in maximum annual deaths among gynecologic cancers with majority of the patients diagnosed at an advanced stage.

Per data provided by the American Cancer Society, approximately 22,440 new cases of ovarian cancer will be diagnosed in the United States in 2017, resulting in more than 14,080 deaths.

Apart from mirvetuximab soravtansine, ImmunoGen is working on developing a couple of other clinical/pre-clinical candidates including IMGN779 and IMGN632. Notably, IMGN779 is being evaluated in a phase I study for treating acute myeloid leukemia (“AML”) with data expected later this year. On the other hand, the company plans to move IMGN632 into clinical development before the year-end to treat hematological malignancies including AML.

ImmunoGen has agreements with several big healthcare companies including Amgen, Bayer, Eli Lilly LLY, Novartis, Roche, Sanofi and Takeda. These contracts allow other companies to use ImmunoGen’s ADC technology and provide it with funds in the form of license and milestone fees, royalties, clinical materials revenues and R&D support fees.  

Notably, in August, ImmunoGen had announced a strategic collaboration and option agreement with Jazz Pharmaceuticals for development and commercialization of the two candidates under ADC programs, IMGN779 and IMGN632. Pursuant to the deal, ImmunoGen would be eligible to receive milestone payments based on certain pre-decided conditions.

Though the platinum-resistant ovarian cancer market offers an immense commercial potential, ImmunoGen is notably set to face intense competition, upon approval. However, mirvetuximab soravtansine looks promising at this juncture and its approval will be a big lift to the company.

ImmunoGen carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Roche Holding AG (RHHBY) : Free Stock Analysis Report
 
Eli Lilly and Company (LLY) : Free Stock Analysis Report
 
Merck & Company, Inc. (MRK) : Free Stock Analysis Report
 
ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

  • Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?
    Business
    Motley Fool

    Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?

    Maybe Wall Street should be called "Weed Street." Big Canadian marijuana grower Canopy Growth listed its stock on the New York Stock Exchange (NYSE) earlier this year. Aurora Cannabis (NASDAQOTH: ACBFF) begins trading on the NYSE on Tuesday, Oct. 23. Aphria (NASDAQOTH: APHQF) filed last week to list its stock on the NYSE.

  • Suze Orman has a killer question for your retirement
    Business
    MarketWatch

    Suze Orman has a killer question for your retirement

    Suze Orman is one of those singular personalities in the financial business who seems to be right on the pulse of everyone she meets. She’s written books, starred in her own television show and made innumerable appearances in person. Like Oprah

  • Better Buy: Ford Motor Company vs. General Motors
    Business
    Motley Fool

    Better Buy: Ford Motor Company vs. General Motors

    Both Ford Motor Company (NYSE: F) and General Motors (NYSE: GM) have been investor favorites in the not-too-distant past, and both pay good dividends. Ford has a slew of new products on the way, starting with a brand-new Ranger pickup early next year. Ford and GM have both had a rough year in the stock market.

  • 3 Warren Buffett Stocks Worth Buying Now
    Business
    Motley Fool

    3 Warren Buffett Stocks Worth Buying Now

    Known as the Oracle of Omaha, Warren Buffett has collected both an incredible investment record and a deservedly vast following among investors of all types. Every move he makes is scrutinized in the hope of gleaning  wisdom from his investment choices.

  • Business
    Investopedia

    Market Sell-Off 80% Over, Will Be Reversed by Stock Repurchases: JPMorgan

    Last week, global markets were hit with a widespread shock that weighed on nearly all asset classes, encompassing even the cryptocurrency space, once viewed as a type of "safe haven" bet unrelated to the broader market. In a note to clients on Thursday, JPMorgan equity strategist Dubravko Lakos-Bujas and team forecasted for U.S. equities to make a comeback as fundamentals come back into play, highlighting stock buybacks as a key driver of the nine-year-bull market, as reported by CNBC.

  • Hate Taxes? 37 States Make Social Security Tax Free
    Business
    Motley Fool

    Hate Taxes? 37 States Make Social Security Tax Free

    Over the course of your career, you'll probably have tens of thousands of dollars in Social Security payroll taxes withheld from your paychecks. Workers are confident that by paying those taxes up front, they'll be able to collect Social Security benefits

  • The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs
    News
    MarketWatch

    The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs

    When the media and investors turn negative on stocks but the “smart money” is bullish, it’s a good time to think about buying. After all, exactly what is the smart money, and how do you know? Lately, several fund managers who pass this test have been pounding the table on Chinese internet names.

  • Why Advanced Micro Devices, Inc. Stock Closed 11% Lower on Friday
    Business
    Motley Fool

    Why Advanced Micro Devices, Inc. Stock Closed 11% Lower on Friday

    Analyst Pierre Ferragu from financial firm New Street Research set his price target for AMD at $18 per share, arguing that the stock has been priced for a level of success that simply isn't realistic. "AMD's stock price reflects a scenario we don't believe possible," Ferragu wrote. In particular, Ferragu sees larger rival Intel (NASDAQ: INTC) getting its manufacturing act together as we speak.

  • Should Congress cut entitlement programs to combat rising deficit?
    Politics
    Fox Business Videos

    Should Congress cut entitlement programs to combat rising deficit?

    Maya MacGuineas, Committee for a Responsible Federal Budget, and Wall Street Journal editorial page deputy editor James Freeman discuss America’s deficit problem and how President Trump asked members of his Cabinet to cut their departments’ budgets by 5 percent.

  • Colorado’s Marijuana Market Just Hit This Huge Milestone
    Business
    Motley Fool

    Colorado’s Marijuana Market Just Hit This Huge Milestone

    Marijuana has been legally available in Colorado for recreational use since 2014, and consumers' appetite for marijuana products continues to grow due to the launch of new products, including concentrates and edibles. As a result, Colorado's annual marijuana sales surpassed $1 billion in August -- the earliest it has ever achieved that milestone. There's been some debate over how much money would move from the black market to regulated markets following legalization, but Colorado's experience suggests it's substantial.

  • 3 Great Stocks Under $10
    Business
    Motley Fool

    3 Great Stocks Under $10

    Among the stocks you can currently purchase for less than $10 per share are Sirius XM Holdings (NASDAQ: SIRI), Annaly Capital Management (NYSE: NLY), and Infosys (NYSE: INFY), and below, we'll take a look at how long they're likely to remain this cheap for would-be investors. Sirius XM was a pioneer in the satellite radio industry, and it's been an investor favorite for years.

  • 3 Energy Stocks You Can Buy and Hold for the Next Decade
    Business
    Motley Fool

    3 Energy Stocks You Can Buy and Hold for the Next Decade

    North America needs to build $23 billion of new natural gas-related infrastructure annually through 2035, according to a recent report. Three of the best positioned to capture this growth are Kinder Morgan (NYSE: KMI), Williams Companies (NYSE: WMB), and TransCanada (NYSE: TRP), making them great stocks to buy and hold in the coming decade. Kinder Morgan is already the largest natural gas pipeline company in North America, operating roughly 70,000 miles of pipeline.

  • Kamala Harris proposes new tax credit
    Politics
    Fox Business Videos

    Kamala Harris proposes new tax credit

    “Bulls & Bears” panel discusses how Sen. Kamala Harris (D-Calif.) is proposing a new tax credit, which would provide families making less than $100,000 a year with an extra $500 a month.

  • Why Valero Energy, eBay, and New Age Beverages Slumped Today
    Business
    Motley Fool

    Why Valero Energy, eBay, and New Age Beverages Slumped Today

    Some major market benchmarks managed to hang onto their gains, but the Nasdaq Composite, and Russell 2000 indexes posted losses of 0.5% to 1.25%, and the S&P 500 was virtually flat. Valero Energy (NYSE: VLO), eBay (NASDAQ: EBAY), and New Age Beverages (NASDAQ: NBEV) were among the worst performers on the day. Valero Energy dropped 10% after the refinery company announced that it would buy back all outstanding units of its related MLP, Valero Energy Partners (NYSE: VLP).

  • Better High-Yield Dividend Stock: PPL Corp. vs. the Southern Company
    Business
    Motley Fool

    Better High-Yield Dividend Stock: PPL Corp. vs. the Southern Company

    Giant diversified U.S. utility The Southern Company (NYSE: SO) offers investors a yield of 5.5%. Globally diversified electric company PPL Corp. (NYSE: PPL) has a yield of 5.4%. Those figures are both at the high end of the utility sector, which might

  • Nearing 10 Years of Dividend Increases, Are These 3 Stocks a Buy?
    Business
    Motley Fool

    Nearing 10 Years of Dividend Increases, Are These 3 Stocks a Buy?

    Brookfield Renewable Partners L.P. (NYSE: BEP), Eaton Corporation plc (NYSE: ETN), and Rockwell Automation Inc. (NYSE: ROK) are all about to hit the decade mark with dividend increases. Brookfield Renewable Partners has nine years of annual dividend increases under its belt, and currently yields a generous 6.7%. The master limited partnership is run by Canadian money manager Brookfield Asset Management and owns, as its name implies, renewable power assets.

  • Finance
    Investopedia

    12 Stocks May Plunge as Investors 'Harvest' Tax Losses

    The fourth quarter began with a big stock market selloff, and many investors may be taking a close look at once-loved stocks in their portfolios that have disappointed with significant price declines this year. "Tax loss selling becomes a possible source

  • These 5 things will kill your early retirement dreams
    News
    MarketWatch

    These 5 things will kill your early retirement dreams

    OUTSIDE THE BOX Early retirement is all the rage these days in personal finance circles. And when I say “early”, I mean really early. I retired at 52 and today’s crowd makes me feel like a slacker. People are retiring in their

  • This Warren Buffett Stock Is Dirt Cheap Right Now
    Business
    Motley Fool

    This Warren Buffett Stock Is Dirt Cheap Right Now

    Warren Buffett has amassed a large portfolio of bank stocks for Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) with major holdings in Bank of America (NYSE: BAC), Wells Fargo (NYSE: WFC), and American Express (NYSE: AXP), just to name a few of the most well-known and largest investments. Synchrony is a major issuer of store-branded credit cards and also operates a rapidly growing online banking platform.

  • 1 Top Stock to Buy Amid October’s Turbulent Market
    Business
    Motley Fool

    1 Top Stock to Buy Amid October’s Turbulent Market

    In the past three weeks alone, stocks have tumbled about 5%, which has many investors unnerved. One top option to consider amid the current turbulence is Magellan Midstream Partners (NYSE: MMP), which has lost more than 5% of its value in the past few weeks. Because of that, investors can get an even better starting price on one of the top master limited partnerships (MLPs), potentially setting themselves up to earn market-beating returns in the coming years.

  • Why PBF Energy Inc and Other Refining Stocks Are Getting Clobbered Today
    Business
    Motley Fool

    Why PBF Energy Inc and Other Refining Stocks Are Getting Clobbered Today

    Shares of PBF Energy Inc (NYSE: PBF) tumbled as much as 10.9% on Friday, joining a sectorwide sell-off that also saw refiners Valero Energy (NYSE: VLO), Phillips 66 (NYSE: PSX), Marathon Petroleum (NYSE: MPC), and HollyFontier (NYSE: HFC) take it on the chin by sinking more than 5% at one point in the day. A trio of factors seems to be driving these declines.

  • Procter & Gamble Finally Has Some Good News for Investors
    Business
    Motley Fool

    Procter & Gamble Finally Has Some Good News for Investors

    It has taken some time, but Procter & Gamble (NYSE: PG) shareholders are finally seeing improving results out of the consumer products titan. P&G paired that positive revenue news with an uptick in profitability, too. P&G's expansion rate sped up significantly, with help from strong sales volumes and steady pricing.

  • These are the bad things about early retirement that no one talks about
    News
    MarketWatch

    These are the bad things about early retirement that no one talks about

    For all the glamour of living an early retirement lifestyle, there are plenty of negatives I’ve come to discover since I permanently left my job in 2012. As a result, you’re repeatedly forced to will yourself into action.

  • Why Procter & Gamble, Skechers USA, and Synchrony Financial Jumped Today
    Business
    Motley Fool

    Why Procter & Gamble, Skechers USA, and Synchrony Financial Jumped Today

    The stock market ended Friday mixed, with the Dow Jones Industrial Average picking up 0.26% even as the Nasdaq Composite and the S&P 500 posted modest declines. Market participants once again responded negatively to news of rising interest rates -- including the 10-year Treasury bond's jump in yield to the 3.2% mark -- as a potential signal that the long bull market in stocks was ending. Procter & Gamble (NYSE: PG), Skechers USA (NYSE: SKX), and Synchrony Financial (NYSE: SYF) were among the best performers on the day.

  • Marijuana investors may lose 90% of their money in Canada, so consider the really big prize elsewhere
    News
    MarketWatch

    Marijuana investors may lose 90% of their money in Canada, so consider the really big prize elsewhere

    Marijuana presents a tremendous opportunity for investors over the next few years. Naïve investors are excited. The reality is that professionals will pick their pockets, and many naïve investors who are excited now will end up losing 90% of their investment.